ResMed Inc (RMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $33.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
ResMed Inc (RMD) Stock Forecast
Analysts expect ResMed (RMD) to earn $12.14 per share in the fiscal year ending Jun 30, 2027, on revenue of $5.83B. Of 20 analysts, 9 rate the stock Buy or Strong Buy, 10 Hold and 1 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Jun 30, 2028, the EPS consensus is $13.23.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 45% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 10.0% |
| Buy | 7 | 35.0% |
| Hold | 10 | 50.0% |
| Sell | 1 | 5.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 20
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.0% and revenue estimates rise 6.5%.
- Fiscal year ending Jun 30, 2027
- $12.14
- EPS consensus, revenue $5.83B
- Fiscal year ending Jun 30, 2028
- $13.23
- EPS consensus, revenue $6.21B
- Next report
- Jan 27, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Jun 30, 2027 | $12.14 | $12.02 to $12.23 | 21 | $5.83B | $5.78B to $5.96B | 29 |
| Jun 30, 2028 | $13.23 | $12.71 to $13.73 | 21 | $6.21B | $5.93B to $6.48B | 29 |
Quarterly Estimates
Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Dec 31, 2026, at $2.99, and highest for the quarter ending Jun 30, 2027, at $3.22.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.99 | $2.93 to $3.13 | 13 | $1.46B | $1.45B to $1.48B | 15 |
| Mar 31, 2027 | $3.06 | $3.02 to $3.10 | 13 | $1.46B | $1.44B to $1.48B | 15 |
| Jun 30, 2027 | $3.22 | $3.02 to $3.42 | 17 | $1.51B | $1.44B to $1.58B | 18 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 9 upward and 28 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Jun 30, 2028 | 8 | 9 |
| Quarter ending Dec 31, 2026 | 1 | 6 |
| Quarter ending Mar 31, 2027 | 0 | 13 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Jun 30, 2027 has risen 1.6% from $11.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Jun 30, 2027 | $12.14 | $12.09 | $12.09 | $12.08 | $11.95 | +1.6% |
| Fiscal year ending Jun 30, 2028 | $13.23 | $13.26 | $13.23 | $13.21 | $13.01 | +1.6% |
| Quarter ending Dec 31, 2026 | $2.99 | $3.02 | $3.03 | $3.04 | $3.01 | -0.8% |
| Quarter ending Mar 31, 2027 | $3.06 | $3.14 | $3.15 | $3.14 | $3.04 | +0.4% |
Frequently Asked Questions About RMD
What is the RMD stock forecast?
Consensus analyst estimates put ResMed's EPS at $12.14 for the fiscal year ending Jun 30, 2027, on revenue of $5.83B. The consensus rating from 20 analysts is Hold.
How do analysts rate RMD stock?
Of 20 analysts covering ResMed, 2 rate it Strong Buy, 7 Buy, 10 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from RMD next year?
For the fiscal year ending Jun 30, 2027, the consensus EPS estimate is $12.14, with estimates from $12.02 to $12.23 from 21 analysts. For the fiscal year ending Jun 30, 2028, the consensus EPS estimate is $13.23, with estimates from $12.71 to $13.73 from 21 analysts.
What revenue do analysts expect from ResMed next year?
For the fiscal year ending Jun 30, 2027, the consensus revenue estimate is $5.83B, with estimates from $5.78B to $5.96B. For the fiscal year ending Jun 30, 2028, the consensus revenue estimate is $6.21B, with estimates from $5.93B to $6.48B.
How many analysts cover RMD?
20 analysts rate ResMed stock, and 21 analysts estimate its EPS for the fiscal year ending Jun 30, 2027.
RMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors